Evidence map›Paper›PMID 26124935›Full record

ArticleIranian journal of basic medical sciences2015

Inhibitory effect of corcin on aggregation of 1N/4R human tau protein in vitro.

Ali Mohammadi Karakani, Gholamhossein Riazi, Seyed Mahmood Ghaffari, Shahin Ahmadian, Farzad Mokhtari, Mahshad Jalili Firuzi, Seyedeh Zahra Bathaie

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in Iranian journal of basic medical sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Current neuropharmacology · 2021
    Review
  17. Review
  18. TheFrontiers in neuroscience · 2019
    Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Ali Mohammadi KarakaniInstitute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran.
Gholamhossein RiaziInstitute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran.
Seyed Mahmood GhaffariInstitute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran.
Shahin AhmadianInstitute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran.
Farzad MokhtariInstitute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran.
Mahshad Jalili FiruziInstitute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran.
Seyedeh Zahra BathaieDepartment of Clinical Biochemistry, Tarbiat Modares University, Tehran, Iran.
University of Tehran · IRTarbiat Modares University · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesAlzheimer's disease (AD) is the most common age-related neurodegenerative disorder. One of the hallmarks of AD is an abnormal accumulation of fibril forms of tau protein which is known as a microtubule associated protein. In this regard, inhibition of tau aggregation has been documented to be a potent therapeutic approach in AD and tauopathies. Unfortunately, the available synthetic drugs have modest beneficial efficacy with several side effects. Therefore, pipeline drugs from natural sources with anti-aggregation properties can be useful in the prevention and treatment of AD. Among medicinal plants, saffron (Crocus sativus, L.), as a traditional herbal medicine has different pharmacological properties and can be used as treatment for several nervous system impairment including depression and dementia. Crocin as a major constituent of saffron is the glycosylated form of crocetin. MATERIALS AND

methodsIn this study, we investigated the inhibitory effect of crocin on aggregation of recombinant human tau protein 1N/4R isoform using biochemical methods and cell culture.

resultsResults revealed that tau protein under the fibrillation condition and in the presence of crocin had enough stability with low tendency for aggregation. Crocin inhibited tau aggregation with IC50 of 100 µg/ml. Furthermore, transmission electron microscopy images confirmed that crocin could suppress the formation of tau protein filaments.

conclusionInhibitory effect of crocin could be related to its interference with nucleation phase that led to increases in monomer species of tau protein. Based on our results, crocin is recommended as a proper candidate to be used in AD treatment.

Indexed as

Alzheimer’s diseaseAnti-aggregationCrocinTau protein

Identifiers

PMID26124935
PMCPMC4475657
OpenAlexW1606707145

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.